Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #666

    Mandagens danske avisuddrag med EU, Mærsk og Ørsted: https://www.proinvestor.com/investornyt/670339/mandagens-danske-avisuddrag-med-eu-maersk-og-orsted

    1 Reply Last reply
    0
    • G Offline
      G Offline
      GeorgeBest
      wrote on sidst redigeret af
      #667

      Private equity firm EQT makes public offer for Swedish pharma maker Recipharm

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #668

        https://www.google.lu/amp/s/www.nasdaq.com/articles/private-equity-firm-eqt-makes-public-offer-for-swedish-pharma-maker-recipharm-2020-12-14%3Famp

        1 Reply Last reply
        0
        • JørgenVarnæsJ Offline
          JørgenVarnæsJ Offline
          JørgenVarnæs
          wrote on sidst redigeret af
          #669

          Det er ikke småpenge, der bliver smidt på de selskaber - mon vi kan tale om et åbent m&a vindue lige nu?

          1 Reply Last reply
          0
          • H Offline
            H Offline
            Hamming
            wrote on sidst redigeret af
            #670

            Lillebror holder R&D dag på onsdag. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-host-virtual-research-development-day-wednesday-december Nogen der følger den?

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #671

              Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab https://www.prnewswire.co.uk/news-releases/novo-holdings-creates-new-rare-bleeding-disorder-company-hemab-854828075.html

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #672
                • Funded through Novo Seeds' company creation and building efforts

                • Focus on rare underserved bleeding disorders with large unmet need

                • Brings together a strong industrial R&D team with deep expertise in hemophilia and clinically validated technologies from Novo Nordisk and Genmab A/S

                1 Reply Last reply
                0
                • V Offline
                  V Offline
                  Vitus
                  wrote on sidst redigeret af
                  #673

                  Utrolig lav omsætning i Genmab....hvad sker der eller hvad sker der ikke ???

                  1 Reply Last reply
                  0
                  • A Offline
                    A Offline
                    AaBforever
                    wrote on sidst redigeret af
                    #674

                    Der sker det som plejer...business as usual..rollercoaster;.)

                    1 Reply Last reply
                    0
                    • A Offline
                      A Offline
                      AaBforever
                      wrote on sidst redigeret af
                      #675

                      😉

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gdn55
                        wrote on sidst redigeret af
                        #676

                        Et gæt kunne være at en del spekulanter, skifter Genmab ud med Bavarian Nordich.H
                        eld og lykke siger jeg bare

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #677

                          A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT04667117?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody+OR+hexabody+OR+Teclistamab+OR+Amivantamab+OR+Talquetamab+OR+Epcoritamab+OR+DuoHexabody&lupd_s=12%2F12%2F2020&draw=2&rank=1

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #678

                            Not long ago it was published in some MS-news that Ocrevus might have this issue with loss of vaccinal immunity. I assume that's why Novartis wants to find out whether that goes for ofa as well. Would not be good. Especially if it is also an issue with the corona vaccines.

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #679

                              I asked Winkel about it in August, but he didn't answer.

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #680

                                But evidence shows that some patients given vaccines to protect against the influenza virus or pneumococcal bacteria lose such immunity after Ocrevus treatment. https://multiplesclerosisnewstoday.com/news-posts/2020/08/21/ocrevus-eliminates-vaccine-immunity-to-varicella-zoster-virus-rrms-patient-case-report/

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #681

                                  It is an issue. We can hope that the way Kesimpta is administered and dose will have less B cell depletion and faster recovery in the case of a pause in treatment; if that is the case Kesimpta would be the preferred drug vs Ocrevus

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #682

                                    i am sure Novartis is getting a lot of questions about this at the moment and I see the trial above just as much in the light of the covid vaccine as the influenze (as i guess you do)

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Rondo
                                      wrote on sidst redigeret af
                                      #683

                                      Ja ja så banker vi på igen igen ....:-)

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #684

                                        anyone following Novo know more about that new company? Will Mim8 move there for example? Will the Duobody licence move there fully, or will Novo nordisk still have access?

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #685

                                          I wonder if it is an issue with weakened virus vaccines only, and not with those based on mRNA?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger